Story perspectives

MIT's Nanoparticles Show Promise Against Ovarian Cancer

10/31/2025

36 6

Summary

Story summary

Massachusetts Institute of Technology (MIT) researchers developed nanoparticles that deliver the immune-stimulating molecule IL-12 directly to ovarian tumors.
In mouse models, combining these nanoparticles with checkpoint inhibitors eliminated metastatic tumors in more than 80% of subjects.
The targeted delivery minimizes systemic side effects associated with high IL-12 doses.
The study, published in Nature Materials, shows immune memory and notes industry partners advancing toward human trials.

1 of 1

Story summary

Massachusetts Institute of Technology (MIT) researchers developed nanoparticles that deliver the immune-stimulating molecule IL-12 directly to ovarian tumors.
In mouse models, combining these nanoparticles with checkpoint inhibitors eliminated metastatic tumors in more than 80% of subjects.
The targeted delivery minimizes systemic side effects associated with high IL-12 doses.
The study, published in Nature Materials, shows immune memory and notes industry partners advancing toward human trials.